Skip to main content
. 2022 Dec 12;44(6):1161–1174. doi: 10.1038/s41401-022-01031-0

Fig. 7. Empagliflozin enhances revascularization in diabetic HLI mice by inhibiting ferroptosis through GPX4.

Fig. 7

a, b Blood perfusion in the ischemic hindlimbs of diabetic HLI mice intramuscularly injected with empagliflozin (10 mg/kg body weight) and shCon or shGPX4 vectors at indicated time points. Representative images (a) and quantification data of blood perfusion ratio were shown (b; n = 7). c Morphological assessment of ischemic hindlimbs in diabetic HLI mice intramuscularly injected with empagliflozin (10 mg/kg body weight) and shCon or shGPX4 vectors at indicated time points (n = 7). d, e Immunofluorescence against PECAM-1 (green) and α-SMA (red) in ischemic hindlimbs tissue of diabetic HLI mice intramuscularly injected with empagliflozin (10 mg/kg body weight) and shCon or shGPX4 vectors at day 21 after surgery. Representative images (d; scale bars: 50 μm) and quantification results (e) were shown. f Representative images of immunohistochemical staining against GPX4 and 4-HNE in ischemic hindlimbs tissues of diabetic HLI mice intramuscularly injected with empagliflozin (10 mg/kg body weight) and shCon or shGPX4 vectors at day 21 after surgery (scale bars: 50 μm). g Transmission electron microscopy images of the mitochondria in the ischemic hindlimbs tissues of diabetic HLI mice intramuscularly administered with empagliflozin (10 mg/kg body weight) and shCon or shGPX4 vectors at day 21 after surgery. Red arrows: mitochondria; scale bars: 200 nm. Data were presented as mean ± SD (n = 6). NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.